These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9473178)

  • 21. Abciximab to prevent vessel closure after angioplasty.
    Med Lett Drugs Ther; 1995 Jun; 37(950):52-3. PubMed ID: 7760769
    [No Abstract]   [Full Text] [Related]  

  • 22. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

  • 23. [The initial experience of the use of ReoPro in high-risk coronary angioplasty in Italy: the Italian Registry on the Conditions for the Use of ReoPro during Angioplasty (R.I.CO.R.D.A.)].
    Simonetti I; Gallopin M; Klugmann S; Gensini GF
    Ital Heart J Suppl; 2000 Jan; 1(1):88-96. PubMed ID: 10832124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do the National Institute of Clinical Excellence guidelines apply to 'real world' use of Abciximab in percutaneous coronary intervention in a teaching hospital setting?
    Khan JM; Watson RD; Varma C; Millane T; Lip GY
    Int J Clin Pract; 2006 Apr; 60(4):498-9. PubMed ID: 16620368
    [No Abstract]   [Full Text] [Related]  

  • 25. Glycoprotein inhibitors and fibrinolysis in myocardial infarction.
    Ring BL
    JAMA; 2000 Dec; 284(24):3124-5. PubMed ID: 11135766
    [No Abstract]   [Full Text] [Related]  

  • 26. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty.
    Garbarz E; Farah B; Vuillemenot A; André F; Angioï M; Machecourt J; Bassand JP; Wolf JE; Danchin N; Prendergast B; Iung B; Vahanian A
    Am J Cardiol; 1998 Sep; 82(6):800-3, A9. PubMed ID: 9761094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
    Mayosi BM; Latouf SE; Commerford PJ
    S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492
    [No Abstract]   [Full Text] [Related]  

  • 28. [Intervention therapy of acute coronary syndrome].
    Yamaguchi T; Nakamura M; Mitsuo K; Matsuda K
    Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1742-8. PubMed ID: 10581757
    [No Abstract]   [Full Text] [Related]  

  • 29. Towards a tailored use of eluted drugs for percutaneous coronary interventions.
    Zimarino M; Ruggieri B; De Caterina R
    Circ J; 2010 Mar; 74(3):424-5. PubMed ID: 20145336
    [No Abstract]   [Full Text] [Related]  

  • 30. [The role of abciximab in the prevention of the acute thrombotic complications of coronary angioplasty].
    Mesquita A; Baptista J; Almeida M; Ferreira J; Machado F; Palos L; Silva A; Seabra-Gomes R
    Rev Port Cardiol; 1997 Dec; 16(12):1031-5. PubMed ID: 9522626
    [No Abstract]   [Full Text] [Related]  

  • 31. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
    Mukherjee D; Topol EJ; Bertrand ME; Kristensen SD; Herrmann HC; Neumann FJ; Yakubov SJ; Bassand JP; McClure RR; Stone GW; Ardissino D; Moliterno DJ;
    Eur Heart J; 2005 Dec; 26(23):2524-8. PubMed ID: 16107485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Counterintuitive contributions to the care of myocardial infarction and the need for randomized trials.
    Morrison DA
    J Am Coll Cardiol; 2003 Sep; 42(6):978-80. PubMed ID: 13678915
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial.
    Cho L; Marso SP; Bhatt DL; Topol EJ
    J Womens Health Gend Based Med; 2000 Sep; 9(7):741-6. PubMed ID: 11025866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study.
    Gyöngyösi M; Domanovits H; Benzer W; Haugk M; Heinisch B; Sodeck G; Hödl R; Gaul G; Bonner G; Wojta J; Laggner A; Glogar D; Huber K;
    Eur Heart J; 2004 Dec; 25(23):2125-33. PubMed ID: 15571828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    De Luca L; Sardella G
    JAMA; 2005 Oct; 294(13):1617; author reply 1617-8. PubMed ID: 16204659
    [No Abstract]   [Full Text] [Related]  

  • 36. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    Osman F; Qaisar S; El Gaylani N; Pitt M
    JAMA; 2005 Oct; 294(13):1616-7; author reply 1617-8. PubMed ID: 16204658
    [No Abstract]   [Full Text] [Related]  

  • 37. [Antithrombotics and interventional cardiology].
    Collet JP; Montalescot G
    Arch Mal Coeur Vaiss; 1999 Nov; 92(11 Suppl):1667-79. PubMed ID: 10598250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty.
    McGregor M; Brophy JM
    Can J Cardiol; 1999 Feb; 15(2):201-7. PubMed ID: 10079780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
    van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
    Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administering abciximab. A new drug for preventing coronary restenosis.
    Strimike CL; Wojcik JM
    Nursing; 1997 Mar; 27(3):32aa-32dd, 32ff. PubMed ID: 9171622
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.